A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Public ClinicalTrials.gov record NCT03173092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 years in participants who previously received a bortezomib-based induction regimen. The study will enroll approximately 160 participants, who are enrolled after completing 3 cycles of chemotherapy (Bortezomib-Based Induction Regimen). They are then treated with Ixazomib in addition to lenalidomide and dexamethasone.
Study identification
- NCT ID
- NCT03173092
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 141 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2017
- Primary completion
- Mar 29, 2026
- Completion
- Mar 29, 2026
- Last update posted
- May 3, 2026
2017 – 2026
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Tucson | Arizona | 85704 | — |
| Los Angeles Cancer Network/(Formerly -Pacific Cancer Medical Center) | Anaheim | California | 92801-1824 | — |
| Compassionate Care Research Group, Inc. | Fountain Valley | California | 92708 | — |
| Innovative Clinical Research | Santa Ana | California | 92705 | — |
| US Oncology Research | Colorado Springs | Colorado | 80907 | — |
| Woodlands Medical Specialists- Pensacola | Pensacola | Florida | 32503 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30303-001 | — |
| Investigator Clinical Research - Indiana | Indianapolis | Indiana | 46260-2082 | — |
| Saint Agnes Hospital | Baltimore | Maryland | 21229 | — |
| American Oncology Partners of Maryland P.A | Bethesda | Maryland | 20817 | — |
| Central Care Cancer Center | Bolivar | Missouri | 65613 | — |
| Kansas City Veterans Affairs Medical Center | Kansas City | Missouri | 64128 | — |
| Comprehensive Cancer Center of Nevada | Henderson | Nevada | 89074 | — |
| Tri-Health Cancer Institute-Medical Oncology and Hematology Westside | Cincinnati | Ohio | 45247 | — |
| Willamette Valley Cancer Institute and Research Center - Springfield | Springfield | Oregon | 97477 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Texas Oncology- Presbyterian Cancer Center Dallas | Dallas | Texas | 75231 | — |
| Texas Oncology-San Antonio Northwest | San Antonio | Texas | 78240 | — |
| Millennium Physicians Association | Shenandoah | Texas | 77380-3256 | — |
| Texas Oncology -Tyler | Tyler | Texas | 75702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03173092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03173092 live on ClinicalTrials.gov.